Sanofi, a drug company in France is trying to get their new insulin, Toujeo approved by the FDA before their patent for the extremely popular Lantus, expires later this year. With the patent expiring, other drug companies like Lilly, and Merck are racing to come up with a cheaper version of the Sanofi original. The popularity of Lantus has given Sanofi a 15% share in the insulin market, the largest share of any single company.
They have been having some issues with the approval of Toujeo. Physicians have said that,while this new product is an improvement on Lantus, it isn't as large of an improvement that Lantus was when it was first released. This statement, especially since it was made by physicians, will discourage the prescribing of Toujeo since it will be more costly. Therefore, the future success of this insulin will depend on what the company chooses to set the price at, and if they can get it approved before the patent expires.
No comments:
Post a Comment